TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Parkinson’s disease Therapeutics Market, by Treatment Type
6.1 Introduction
6.2 Medications
6.2.1 Dopamine Precursors
6.2.2 Peripheral Decarboxylase Inhibitors
6.2.3 COMT Inhibitors
6.2.4 MAO Inhibitors
6.2.5 Others
6.3 Surgical Therapy
6.3.1 Deep Brain Stimulation (DBS)
6.3.2 Carbidopa/Levodopa Enteral Suspension
Chapter 7. Global Parkinson’s disease Therapeutics Market, by End-User
7.1 Introduction
7.2 Hospitals & Clinics
7.3 Academic & Industrial Research
7.4 Others
Chapter 8. Global Parkinson’s disease Therapeutics Market, by Region
8.1 Introduction
8.2 America
8.2.1 North America
8.2.1.1 U.S.
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K.
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9. Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 Salix Pharmaceuticals
10.1.1 Company Overview
10.1.2 Type Overview
10.1.3 Financials
10.2.4 Key Developments
10.1.5 SWOT Analysis
10.2 GlaxoSmithKline Plc
10.2.1 Company Overview
10.2.2 Type Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Impax Laboratories, LLC
10.3.1 Company Overview
10.3.2 Type Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Teva Pharmaceutical Industries Ltd
10.4.1 Company Overview
10.4.2 Type/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Novartis AG
10.5.1 Company Overview
10.5.2 Type Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Orion Corporation
10.6.1 Company Overview
10.6.2 Type Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Mylan N.V.
10.7.1 Overview
10.7.2 Type Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Par Pharmaceutical
10.8.1 Overview
10.8.2 Type Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Cipla Inc.
10.9.1 Overview
10.9.2 Type Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Daiichi Sankyo
10.10.1 Overview
10.10.2 Type Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.11 Apotex Inc.
10.11.1 Overview
10.11.2 Type Overview
10.11.3 Financials
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.12 Wockhardt Limited
10.12.1 Overview
10.12.2 Type Overview
10.12.3 Financials
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.13 ACADIA Pharmaceuticals Inc
10.13.1 Overview
10.13.2 Type Overview
10.13.3 Financials
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.14 Abbott
10.14.1 Overview
10.14.2 Type Overview
10.14.3 Financials
10.14.4 Key Developments
10.14.5 SWOT Analysis
10.15 Others
Chapter 11 Appendix
LIST OF TABLES
Table 1 Global Parkinson’s disease Therapeutics Market Industry Synopsis, 2023-2030
Table 2 Global Parkinson’s disease Therapeutics Market Estimates & Forecast, 2023-2030, (USD Million)
Table 3 Global Parkinson’s disease Therapeutics Market, by Region, 2023-2030, (USD Million)
Table 4 Global Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 6 Global Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 7 North America Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 9 North America Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 10 U.S. Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 11 U.S. Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 12 Canada Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 13 Canada Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 14 South America Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 15 South America Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 16 Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 17 Europe Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 18 Western Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 19 Western Europe Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 20 Eastern Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 21 Eastern Europe Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 22 Asia Pacific Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 23 Asia Pacific Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
Table 24 The Middle East & Africa Parkinson’s disease Therapeutics Market, by Treatment Type, 2023-2030, (USD Million)
Table 25 The Middle East & Africa Parkinson’s disease Therapeutics Market, by End-User, 2023-2030, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Parkinson’s disease Therapeutics Market
Figure 3 Market Dynamics for Global Parkinson’s disease Therapeutics Market
Figure 4 Global Parkinson’s disease Therapeutics Market Share, by Treatment Type, 2023
Figure 5 Global Parkinson’s disease Therapeutics Market Share, by End-User, 2023
Figure 6 Global Parkinson’s disease Therapeutics Market Share, by Region, 2023
Figure 7 North America Parkinson’s disease Therapeutics Market Share, by Country, 2023
Figure 8 Europe Parkinson’s disease Therapeutics Share, by Country, 2023
Figure 9 Asia Pacific Parkinson’s disease Therapeutics Market Share, by Country, 2023
Figure 10 The Middle East & Africa Parkinson’s disease Therapeutics Market Share, by Country, 2023
Figure 11 Global Parkinson’s disease Therapeutics Market: Company Share Analysis, 2023 (%)
Figure 12 Abbott: Key Financials
Figure 13 Abbott: Segmental Revenue
Figure 14 Abbott: Geographical Revenue
Figure 15 Salix Pharmaceuticals: Key Financials
Figure 16 Salix Pharmaceuticals: Segmental Revenue
Figure 17 Salix Pharmaceuticals: Geographical Revenue
Figure 18 GlaxoSmithKline Plc: Key Financials
Figure 19 GlaxoSmithKline Plc: Segmental Revenue
Figure 20 GlaxoSmithKline Plc: Geographical Revenue
Figure 21 Impax Laboratories, LLC: Key Financials
Figure 22 Impax Laboratories, LLC: Segmental Revenue
Figure 23 Impax Laboratories, LLC: Geographical Revenue
Figure 24 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 25 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 26 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 27 Novartis AG: Key Financials
Figure 28 Novartis AG: Segmental Revenue
Figure 29 Novartis AG: Geographical Revenue
Figure 30 Orion Corporation: Key Financials
Figure 31 Orion Corporation: Segmental Revenue
Figure 32 Orion Corporation: Geographical Revenue
Figure 33 Mylan N.V.: Key Financials
Figure 34 Mylan N.V.: Segmental Revenue
Figure 35 Mylan N.V.: Geographical Revenue
Figure 36 Par Pharmaceutical: Key Financials
Figure 37 Par Pharmaceutical: Segmental Revenue
Figure 38 Par Pharmaceutical: Geographical Revenue
Figure 39 Cipla Inc.: Key Financials
Figure 40 Cipla Inc.: Segmental Revenue
Figure 41 Cipla Inc.: Geographical Revenue
Figure 42 Daiichi Sankyo: Key Financials
Figure 43 Daiichi Sankyo: Segmental Revenue
Figure 44 Daiichi Sankyo: Geographical Revenue
Figure 45 Apotex Inc.: Key Financials
Figure 46 Apotex Inc.: Segmental Revenue
Figure 47 Apotex Inc.: Geographical Revenue
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
